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ABSTRACT
Objectives: To develop an internationally validated
measure of cancer awareness and beliefs; the
awareness and beliefs about cancer (ABC) measure.
Design and setting: Items modified from existing
measures were assessed by a working group in six
countries (Australia, Canada, Denmark, Norway, Sweden
and the UK). Validation studies were completed in the UK,
and cross-sectional surveys of the general population
were carried out in the six participating countries.
Participants: Testing in UK English included cognitive
interviewing for face validity (N=10), calculation of
content validity indexes (six assessors), and
assessment of test–retest reliability (N=97). Conceptual
and cultural equivalence of modified (Canadian and
Australian) and translated (Danish, Norwegian, Swedish
and Canadian French) ABC versions were tested
quantitatively for equivalence of meaning (≥4
assessors per country) and in bilingual cognitive
interviews (three interviews per translation). Response
patterns were assessed in surveys of adults aged
50+ years (N≥2000) in each country.
Main outcomes: Psychometric properties were
evaluated through tests of validity and reliability,
conceptual and cultural equivalence and systematic
item analysis. Test–retest reliability used weighted-κ
and intraclass correlations. Construction and validation
of aggregate scores was by factor analysis for
(1) beliefs about cancer outcomes, (2) beliefs about
barriers to symptomatic presentation, and item
summation for (3) awareness of cancer symptoms and
(4) awareness of cancer risk factors.
Results: The English ABC had acceptable test–retest
reliability and content validity. International
assessments of equivalence identified a small number
of items where wording needed adjustment. Survey
response patterns showed that items performed well in
terms of difficulty and discrimination across countries
except for awareness of cancer outcomes in Australia.
Aggregate scores had consistent factor structures
across countries.
Conclusions: The ABC is a reliable and valid
international measure of cancer awareness and beliefs.
The methods used to validate and harmonise the ABC
may serve as a methodological guide in international
survey research.
ARTICLE SUMMARY
Article focus
▪ Knowledge and beliefs about cancer have been
implicated in delay in symptomatic presentation
which can reduce the proportion of cancers diag-
nosed at an early stage and lead to lower survival
rates.
▪ Existing studies of knowledge and beliefs have
focused on individual countries, but international
differences may also contribute to international
differences in cancer survival.
▪ This paper describes the development of an
internationally validated measure of cancer
knowledge and beliefs; the awareness and beliefs
about cancer (ABC) measure.
Key messages
▪ The ABC is a reliable, validated instrument for
measuring knowledge and beliefs about cancer.
▪ Validated versions have been developed for six
countries (the UK, Australia, Canada, Sweden,
Denmark and Norway) and in five languages
(English, Canadian French, Swedish, Danish and
Norwegian).
▪ The development of the ABC provides a blueprint
for other countries that wish to examine their
citizens’ ABC.
Strengths and limitations of this study
▪ The approach used to validate this international
measure, which has evolved from current guide-
lines, should be useful to other researchers car-
rying out international surveys.
▪ Improvements could still be made to the measures
as a small number of items did not perform well in
one or the other of the reliability or validity tests.
▪ Initial item selection for the ABC measure was
hampered by a lack of pre-existing validated
measures of cancer beliefs.
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INTRODUCTION
Internationally, there are variations in cultural attitudes
to cancer, provision of public education about cancer
and delivery of healthcare. These may shape awareness
or beliefs about cancer, and ultimately lead to differ-
ences in early detection behaviours that could partly
explain international differences in the proportion of
cancers diagnosed at an early stage.1 2
An internationally valid measure of awareness and
beliefs about cancer (ABC) is essential to take forward
this research. There are challenges associated with using
measures developed in one language and culture in
international surveys,3 4 but guidelines are available to
support the development of internationally reliable and
valid measures.3 5 One key issue is that direct,
word-for-word translations are not always appropriate
where the aim is to be culturally sensitive and yet assess
the same constructs. Psychometric properties also need
to be checked in each country where it is used to ensure
that any observed international differences are not due
to measurement error.6
In the cancer ﬁeld, a variety of human and system
factors have been identiﬁed as potential determinants of
patient delay in the presentation of cancer symptoms.
Lack of awareness of possible early cancer symptoms can
inﬂuence attributions and interpretation,7 and reduce
the chance of rapid help-seeking.8 Research in the UK
has shown that lower symptom awareness is associated
with a lower likelihood of attributing symptoms to
cancer, and longer intended delay in help-seeking.7 9 10
Fatalistic attitudes about survival have also been linked
with lower screening uptake and greater delay in symp-
tomatic presentation.11 12 Perceived or actual barriers to
accessing medical care may also play a deterrent role.7 9
We have only found one validated measure of cancer
awareness,13 and it did not include items on beliefs or
attitudes, and has not been assessed internationally.
This paper describes the development and validation
of an international measure: ABC measure. The ABC
was developed systematically to maximise equivalence
across the countries of the International Cancer
Benchmarking Partnership (ICBP; Australia, Canada,
Denmark, Norway, Sweden and the UK) to identify dif-
ferences in awareness and beliefs that could explain
established differences in cancer survival.
METHODS
Item selection
Item selection for the ABC was informed by theoretical
frameworks outlining processes of patient delay,14 15 the
English Department of Health’s National Awareness and
Early Diagnosis pathway16 and existing surveys.13 17–19
An initial item pool was assessed by the ICBP Working
Group with representatives from all participating coun-
tries. This resulted in selection of 32 ‘core’ items, plus
modules on cancer screening (8 items) and risk factors
(13 items). The ABC was designed to be administered
by telephone interview in order to be practical for data
collection across diverse geographic areas.
The core measure included (1) awareness of cancer
symptoms (1 open ‘symptom recall’ item, 11 closed
‘symptom recognition’ items), (2) awareness of cancer out-
comes (4 items), (3) help-seeking intentions (4 items),
(4) beliefs about cancer; including beliefs about outcomes
and the value of early presentation (6 items), (5) beliefs
about barriers to symptomatic presentation (5 items) and
(6) estimated age at which people are most likely to
develop cancer (1 item). The optional modules were
awareness of risk factors for cancer (13 ‘risk factor recogni-
tion’ items) and beliefs and behaviour in relation to breast
and colorectal screening (8 items). One module assessing
ovarian cancer awareness was administered only in Wales
(Brain KE, personal communication, 2012). The full and
ﬁnal version (postvalidation) of the UK ABC measure,
including response categories, can be viewed in the online
supplementary ﬁle.
Four aggregate scores were developed during testing.
Symptom awareness and risk factor awareness aggregate
scores were calculated by adding the total number of
items endorsed from the recognition lists. ‘Barriers to
symptomatic presentation’ and ‘beliefs about cancer out-
comes’ aggregate scores were created using weights
derived from factor analyses (see section on
International validity for a full description of the above).
Pilot testing
The draft ABC was piloted in UK English before transla-
tion and testing in Australian English, Canadian English,
Canadian French, Danish, Swedish and Norwegian. Data
collection for the validated studies took place in
January–May 2011 and was carried out by a market
research company (Ipsos MORI, London, UK) and
members of the ICBP Working Group. Statistical ana-
lyses used the IBM SPSS V.19 and Stata V.12 computer
software packages.
UK testing: reliability and validity
Cognitive interviews were carried out by telephone with
10 people aged ≥50 years; this age group was selected
because it was the primary target group for the inter-
national survey. A trained interviewer asked participants
to read each item and answer it while ‘thinking aloud’.20
This process identiﬁed items where the participant’s
understanding differed from the interviewer’s, or where
the items caused confusion or distress.
Test–retest reliability was assessed in 97 adults aged
≥50 years (55% women, 45% ≥65 years), who completed
the ABC on the telephone twice, 2 weeks apart.
Agreement over time was assessed with a combination of
linear weighted-κ for individual (ordinal) items, and
intraclass correlations (ICC consistency) for aggregate
(continuous) scores (total number of symptoms/risk
factors recognised, barriers to symptomatic presentation
and beliefs about cancer outcomes).21 The magnitude
of the associations was judged according to
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classiﬁcations proposed by Landis and Koch22 and
Cicchetti.23 Internal consistency of aggregate scores was
assessed with Cronbach’s α.
A content validity assessment was carried out by six
independent academic researchers with expertise in psy-
chometrics or cancer awareness, to assess both the
clarity and the relevance of the items against the prede-
ﬁned constructs.24 Each item was scored (1=poor to
4=excellent) on clarity and on relevance to the con-
struct. Raters were asked for comments on any items
scoring less than 3. For each item, and each set of items
measuring any one construct, we calculated a Content
Validity Index (CVI) (number of raters giving rating of
3–4/total number of raters). There is no universal agree-
ment on the deﬁnition of an adequate CVI score; we
used the criterion of >78%25 because with six raters, this
allows only one rater to score below ‘3’ on any item, fol-
lowing the recommendation by Lynn.26
International testing: quality and validity
of translated measures
The ABC was then translated into Danish, Swedish,
Norwegian and Canadian French. Minor amendments
to UK English version were also made for the Australian
and Canadian English versions. Translations were done
by native speakers who also spoke good English and
were familiar with medical terminology, and were
checked by bilingual members of the ICBP Working
Group. Items were rephrased as needed to reﬂect differ-
ences in healthcare systems or other cultural contexts.
We aimed for conceptual and cultural equivalence
rather than a verbatim translation. The process used to
achieve this was informed by the WHO guidelines,4 the
International Workshop on Comparative Survey Design
and Implementation (http://www.csdiworkshop.org/),
as well as other guidelines for cross-cultural adaptation.5
We also drew on processes followed in other inter-
national studies27 28 to develop a method appropriate to
the current project.
Up to 10 (range=8–10) cognitive interviews using the
ﬁnal versions were carried out with people aged 50+ in
each country except for Canada, which carried out 10
each in French and English. Interviews took place over
the telephone except in Denmark, where they were
face-to-face. The interviews led to minor changes which
were discussed collaboratively with members of the ICBP
Working Group in each country to reach consensus.
Quantitative assessment of equivalence of meaning
Quantitative assessment of equivalence and relevance
was carried out for the French, Swedish, Danish and
Norwegian versions of the ABC.29 The process was
analogous to the UK content validity testing, but focused
on conceptual and cultural equivalence. Each country
assembled 4–8 experts in the ﬁeld who were ﬂuent in
both the relevant target language and English and who
were not members of the ICBP Working Group.25 30
They scored the items (and introductory sentences and
response options) from 1 (poor) to 4 (excellent) on
equivalence of meaning comparing the local translation
to the UK ABC, and relevance to the constructs as
understood within each cultural setting. A CVI score was
calculated in the same way as for the UK (see above)
with a cut-off of 78% representing adequate agreement.
Bilingual cognitive interviewing
Three further telephone cognitive interviews were carried
out with non-expert bilingual translators (the target lan-
guage plus English) for each version of the ABC. This
checked that changes made throughout the adaptation
process had not led to divergence of meaning. At this
stage, members of the ICBP Working Group from the
three Scandinavian countries also carried out a check to
ensure equivalence in Danish, Norwegian and Swedish
because of their close linguistic links.
International validity of items and constructs
As part of the validation process, we explored the equiva-
lence of the data collected across participating countries.
After completing a tendering process, ABC surveys were
carried out by a market research company (Ipsos MORI)
between May and September 2011 using computer-
assisted telephone interviews. The aim was to draw
population-representative samples with a minimum of
2000 people aged 50+ completing the core ABC measure
in each country. The method is described brieﬂy here
and further details can be found elsewhere.31 In the UK,
Canada and Australia, random samples of telephone
numbers were drawn from commercial listings. The ﬁnal
two digits of each selected telephone number were
replaced with two random numbers, which brought
unlisted numbers into the sampling frame. Where there
was more than one eligible person living in the house-
hold, one person was selected using the ‘Rizzo’ method
to ensure an equal chance of selection for interview.32 In
the Scandinavian countries random samples of eligible
people were drawn from complete population registers
and linked to commercial telephone listings. Additional
age ranges and extra modules were completed in some
countries (see table 1). Ethical approval for the survey
was secured via local ethics boards in each participating
jurisdiction, with the exception of Norway where ethical
approval was not required. Interviewers took part in
survey-speciﬁc training to ensure consistency and sensitiv-
ity. In total, 19 079 people completed the interview. The
response rate (American Association for Public Opinion
Research response rate formula3; http://www.aapor.org)
ranged from 23% in Norway to 47% in Australia. Samples
were roughly population-representative for age, but
women were over-represented (59% vs 53% in the popu-
lation aged 50+). Weights were calculated and applied,
where appropriate, to adjust for recruitment method,
population size and non-response bias.
We assessed how ‘well’ the items performed (discrim-
ination and difﬁculty) by examining the consistency of
response patterns across countries using the full
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international dataset. For each country, we identiﬁed
items with very low variation (≥95% of participants
answering in the same category). In a second analysis we
examined the proportions of ‘invalid’ responses. In the
main, we considered ‘don’t know’, ‘refused’ or a blank
(no answer recorded) as ‘invalid’.i We judged that where
>10% of responses were ‘invalid’, the item was too difﬁ-
cult. Large variations between countries in this analysis
were taken as an indication that items might not be
equivalent, and therefore that good functional transla-
tion might not have been achieved.
We explored the performance of the two variables
derived as aggregated combinations of items weighted to
align with latent constructs. Items selected for inclusion
in the aggregate scores had adequate mutual intercorre-
lations. ‘Barriers to symptomatic presentation’ combined
four items (too embarrassed, too busy, worried about
wasting the doctor’s time and worried about what the
doctor might ﬁnd). ‘Beliefs about cancer outcomes’
combined three items (‘cancer can(not) often be
cured’, ‘a diagnosis of cancer is a death sentence’ and
‘people with cancer can(not) expect to continue with
normal activities and responsibilities’). Having checked
that the Cronbach’s α for the items in each score were
above 0.45, factor analysis was applied to the mutual
item intercorrelations to identify the latent factor that
maximally accounted for common variation.33 Means of
the six country-speciﬁc factor-based weighting coefﬁ-
cients were used as the coefﬁcients for the overall aggre-
gate scores to be applied across all countries. Validity
was deﬁned in two ways: (1) a unipolar, general factor
should account for a proportion of the communality
exceeding the baseline level by 40% in each country
and (2) the resultant weighting coefﬁcients should be
consistent across countries. This was checked by examin-
ing the correlations of the overall aggregate score with
the local equivalents derived in each country.
RESULTS
UK testing
As a result of the UK cognitive interviews, minor adjust-
ments were made to the wording of 12 items and ﬁve
response options and some of the introductory text was
modiﬁed to improve clarity and accessibility.
The internal consistency for the aggregate symptom
and risk factor scores was good (Cronbach’s α >0.70),
but internal consistency was lower for the aggregate
scores for barriers to symptomatic presentation (0.52)
and beliefs about cancer outcomes (0.49). The relatively
low α values follow from the relatively low correlations
among the constituent questions (range 0.2–0.4). While
the communality variance of the constituent questions is
lower than ideal for deﬁnition of a latent factor, a
balance is evident in that each constituent question con-
tains substantial unique information.
In test–retest reliability analyses, the aggregate scores
all reached ‘substantial’ (≥60%) agreement between
administrations. ICC were also good (total symptoms
r=0.70, total risk factors r=0.67, barriers to symptomatic
presentation r=0.62, beliefs about cancer outcomes
r=0.61).
The majority of individual items had a good agree-
ment between the two administrations, but three fell
below 20%. These were one item in the ‘screening’
module (‘breast cancer screening could reduce my
chances of dying from breast cancer’, k=0.11), and two
items in the ‘risk factor module’ (smoking, k=−0.02; sun
bed use, k=−0.04). The breast screening item was tested
only in women (N=53), 10 changed their response
between test and retest, of whom 7 changed more than
two points on the response scale. Clearly this belief is
not temporally stable, possibly reﬂecting the public’s
confusion about the primary purpose of screening and
this is likely to vary between countries. For the risk
factor items, the κ-coefﬁcient was affected by the very
small numbers who ‘disagreed’ with these items at the
ﬁrst administration (two and seven, respectively) who all
‘agreed’ at the second administration. In fact the over-
whelming majority of participants ‘agreed’ at both time
points and as these items are well-established risk factors
for cancer they were retained.
Table 1 Participation in the international survey of cancer awareness and beliefs
England
Northern
Ireland Wales
Australia
NSW
Australia
Victoria Canada Denmark Sweden Norway
Core ABC (2000 aged 50+) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Module 1—screening (2000
aged 50+)
✓ – – ✓ – – ✓ ✓ ✓
Module 2—risk awareness (2000
aged 50+)
– ✓ – – – – ✓ ✓ ✓
Module 3—ovarian cancer
awareness (women aged 50+)
– – ✓ – – – – – –
ABC—younger sample (1000
aged 30–49)
– – – – – – ✓ ✓ ✓
ABC, awareness and beliefs about cancer; NSW, New South Wales.
iFor items on symptom awareness (q09–q19), ‘don’t know’ was offered
as a response and considered a ‘valid’ answer, following previous
analyses.9
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Content validity assessment showed good (>78%)
agreement for all individual items for clarity and rele-
vance. Raters also made a content validity assessment of
groups of items representing the different areas (con-
structs described in ‘item selection’ section). The overall
clarity rating for the ‘barriers’ construct was 67%, which
the raters’ noted was because of lack of clarity in the
introductory sentences.
International testing: conceptual and cultural equivalence
A number of translation issues were highlighted by the cog-
nitive interviews. The verbal interviewer script was shor-
tened and changes made to item ordering to enhance the
‘ﬂow’ of the interview. Additional explanations for some
terms (eg, ‘persistent’, ‘HPV’ and ‘processed meat’) were
either added or made available to interviewers for respon-
dents who needed further explanation.
Quantitative assessment of equivalence of meaning
In general, the items achieved high ratings of equiva-
lence and relevance in the quantitative assessment of
the quality of translation. Table 2 shows the number of
items that performed less well. Overall, more problems
in the translations were identiﬁed by the ‘equivalence’
than the ‘relevance’ test. The common issues included:
the translation and coding of the ‘help-seeking
intentions’ items, the wording of the item about ‘difﬁ-
culty getting an appointment with a doctor’, the transla-
tion of ‘embarrassment’ as a barrier to seeking medical
help and the wording of the screening module items
because of the local characteristics of screening pro-
grammes. Discussion of the intended meaning of the
items took place between the ICBP Working Group and
the research company team to enable translators to
reword these items to ensure equivalence of meaning.
These adjustments were checked during the bilingual
cognitive interviews, where a few further minor adjust-
ments were made.
International validity of items and constructs
Table 3 shows the items that performed less well in
terms of either difﬁculty or discrimination in the inter-
national surveys. Very few items were non-discriminatory;
the exceptions were awareness of ‘change in the appear-
ance of a mole’ and ‘unexplained lump or swelling’,
which were recognised as symptoms of cancer by over
95% of participants in most countries. This indicates
that they are well-known symptoms and analyses using
them as single-item variables would have limited useful-
ness; however, they were included on the grounds of
face validity. The items with the highest number of
‘invalid’ responses were those asking: “Out of 10 people
Table 2 Results of the quantitative assessment of equivalence of meaning—number of items with agreement index <78%
Module
Canadian French
(N=4 raters)
Danish
(N=6 raters)
Swedish
(N=8 raters)
Norwegian
(N=6 raters)
Core module (32 items)
Equivalence 6 4 6 5
Relevance 5 2 0 3
Risk factors module (13 items)
Equivalence – 0 0 0
Relevance – 0 0 0
Screening module (8 items)
Equivalence – 0 4 2
Relevance – 2 0 2
Table 3 Items that performed less well in terms of either difficulty or discrimination
Item (category)* The UK Australia Canada Denmark Sweden Norway
Non-discrimination (>95% in any single category) (%)
Knowledge of unexplained lump or swelling as a symptom of
cancer (Yes)
96.6 95.7 – – – –
Q15—change in the appearance of a mole (Yes) 96.7 98.2 95.4 97.0 96.5 98.3
High % ‘invalid’ (>10%)
Q29—cancer treatment is worse than cancer itself (tend to
agree)
15.9 – – 11.1 10.6 –
Q34—how many out of 10 survive bowel cancer (5 people) – 12.1 – – – –
Q35—how many out of 10 survive breast cancer (8 people) – 10.3 – – – –
Q36—how many out of 10 survive ovarian cancer (5 people) 14.9 21.1 10.1 – – –
Q37—how many out of 10 survive lung cancer (5 people) – 12.9 – – – –
*The full range of response options for each item can be seen in the online supplementary file containing the UK ABC measure.
ABC, awareness and beliefs about cancer.
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diagnosed with X cancer, how many do you think would
be alive 5 years later.” In particular, the ovarian cancer
outcomes item performed poorly in both women and
men. Participants in Australia tended to ﬁnd all of the
items about cancer outcomes difﬁcult to answer.
Results of analyses exploring the comparability of the
factor structure of aggregate scores across countries are
shown in tables 4 and 5 which show the percentage of
communality accounted for by the ﬁrst factor and the
factor score coefﬁcients for each country. Also shown
are the correlations of the overall aggregate score with
each country’s factor score variable, and the means that
were used to generate the overall aggregate scores. The
percentage of communality explained by the ﬁrst factor
was consistently at least 40% above the baseline level for
the number of factors extracted, which is considered sat-
isfactory. Correlations between the overall measure and
the factor scales in each country were >0.99 except for
one instance of 0.98. This was considered satisfactory.
DISCUSSION
This paper describes the methods used to develop an
international measure of cancer awareness and beliefs
administered by telephone interview. Good test–retest
reliability and internal and content validity were estab-
lished in a UK sample prior to translation into other
languages. The process of adaptation targeted concep-
tual and cultural equivalence rather than verbatim trans-
lation. To determine where changes to a direct
translation were needed to reﬂect this goal, we used a
process comparable to a quantitative content validity
exercise with expert raters assessing items in terms of
equivalence and relevance. This highlighted items
needing revision in order to achieve equivalence of
meaning across cultures.
Overall, the ABC measure showed good international
validity as assessed by consistency in item performance
and the factor structure of aggregate scores. Although
the Cronbach’s α for the aggregate scores were some-
what low, factor analysis results and stability across coun-
tries demonstrated that the latent variable was well
deﬁned. A small number of items did not perform well
in the reliability or validity tests. Some of these were
retained for face validity; in other cases they were
retained because of the disproportionate time invest-
ment needed to repeat the validation process in all the
languages for a small number of items. Improvements
could still therefore be made to the measure in the
future.
Another limitation was that the selection of the initial
items to include in the ABC measure was hampered by
lack of preexisting validated measures of cancer beliefs.
Although there are validated measures for some areas, for
Table 4 Development and validation of the aggregate score: barriers to symptomatic presentation
Country
Factor score coefficients
Communality
explained (%)*
Correlation with
aggregate score
Q24 ‘too
embarrassed’
Q25 ‘time
wasting’
Q26 ‘what the
dr might find’
Q27 ‘too
busy’
Canada 1.1330 0.3925 0.4860 0.3626 41.4 0.989
The UK 0.9129 0.4206 0.3709 0.3561 42.4 0.996
Australia 1.2711 0.4797 0.4356 0.3695 39.8 0.997
Denmark 1.5537 0.7108 0.2863 0.3098 39.7 0.992
Norway 1.3142 0.6716 0.3616 0.3147 39.6 0.999
Sweden 1.0438 0.8786 0.3046 0.3002 34.7 0.984
†Mean 1.2048 0.5935 0.3742 0.3355
*The target is ≥35% (a 40% excess above the baseline of 25%).
†The mean factor score coefficients become the weights for the aggregate score.
Table 5 Development and validation of the aggregate score: negative beliefs about cancer outcomes
Country
Factor score coefficients Communality
explained (%)*
Correlation with
aggregate scoreQ28 ‘normal activities’ Q31 ‘cure’ Q33 ‘death sentence’
Canada 0.4319 0.5327 0.2724 50.0 0.991
The UK 0.3776 0.6330 0.2895 50.0 0.998
Australia 0.4185 0.6664 0.2385 50.2 0.999
Denmark 0.3242 0.7554 0.2367 50.2 0.998
Norway 0.3462 0.8330 0.2182 46.1 0.996
Sweden 0.3549 0.7936 0.2453 47.0 0.998
†Mean 0.3756 0.7024 0.2501
*The target is ≥47% (a 40% excess above the baseline of 33%).
†The mean factor score coefficients become the weights for the aggregate score.
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example for breast cancer fear34 and cancer fatalism,35
these did not encompass the variety of beliefs potentially
associated with help-seeking behaviour. The ﬁeld would be
enhanced by research into the full range of beliefs about
cancer. The two belief constructs validated in the ABC (bar-
riers to symptomatic presentation and beliefs about cancer
outcomes) are a start on this process.
The ABC is a reliable and valid measure of cancer
awareness and beliefs available in ﬁve languages
(English, Danish, Swedish, Norwegian and Canadian
French), and with demonstrable international validity.
The development provides a blueprint for other coun-
tries who wish to compare their citizens’ ABC with those
of the ICBP partners. This approach to validating inter-
national measures, which has evolved from the guide-
lines on the topic, should also be useful for other
international survey research.
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